Viatris Innovation GmbH
Clinical trials sponsored by Viatris Innovation GmbH, explained in plain language.
A German subsidiary of Viatris, a global healthcare company making generic and branded medicines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New blood thinner tested in small chinese heart study Results expected Oct 2026 (estimated)
- New lupus pill shows promise in major trial Results expected Dec 2026 (estimated)
- New pill could tame lupus flares in major trial Results expected Mar 2027 (estimated)
- Could a Pen-Sized shot stop a heart attack in its tracks? Results expected Jul 2027 (estimated)
-
New hope for lupus patients: drug trial targets kidney damage
Disease control Recruiting nowThis study tests if a new drug called cenerimod can help people with lupus who have active kidney disease (lupus nephritis). About 300 adults will take either cenerimod or a placebo daily for 76 weeks, on top of their usual treatments. The main goal is to see if cenerimod improve…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New blood thinner tested in small chinese heart study
Knowledge-focused Recruiting nowThis early-stage trial will study how a single 16 mg dose of selatogrel, an injectable blood thinner, is absorbed and tolerated in 20 Chinese adults with chronic coronary syndrome. Participants will stay at a clinic for a few days and receive either selatogrel or a placebo. The g…
Phase 1 • Sponsor: Viatris Innovation GmbH • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC